SCHEMBL30470352

SCHEMBL30470352

CN1CCC[C@@H](n2cc3cc(B4OC(C)(C)C(C)(C)O4)ccc3n2)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.34
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
MLLT1 Q03111 1/20 0.33
LPL P06858 2/20 0.31
LIPG Q9Y5X9 2/20 0.31
SNCA P37840 1/20 0.31
IRAK4 Q9NWZ3 1/20 0.31
JAK1 P23458 3/20 0.31
JAK3 P52333 3/20 0.31
JAK2 O60674 1/20 0.31
OPRM1 P35372 2/20 0.31
OPRD1 P41143 2/20 0.31
OPRK1 P41145 2/20 0.31
OPRL1 P41146 2/20 0.31
KDM5A P29375 1/20 0.30
HDAC1 Q13547 3/20 0.30
HDAC8 Q9BY41 3/20 0.30
HDAC6 Q9UBN7 3/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30469913 1.00 TLR8 (0.34) TLR8IDO1TDO2MLLT1LPL
SCHEMBL25319208 0.94 TLR8 (0.35) TLR8IDO1TDO2LPLLIPG
SCHEMBL25321106 0.94 TLR8 (0.35) TLR8IDO1TDO2LPLLIPG
SCHEMBL29082062 0.89 TLR8 (0.35) TLR8IDO1TDO2LPLLIPG
SCHEMBL29081352 0.87 TLR8 (0.39) TLR8IDO1TDO2LPLLIPG
SCHEMBL25334207 0.85 LPL (0.34) TLR8IDO1TDO2LPLLIPG
SCHEMBL25334200 0.85 LPL (0.34) TLR8IDO1TDO2LPLLIPG
SCHEMBL25958846 0.85 LPL (0.34) TLR8IDO1TDO2LPLLIPG
SCHEMBL27006046 0.81 IRAK4 (0.38) TLR8IDO1TDO2LPLLIPG
SCHEMBL25323782 0.81 TLR8 (0.34) TLR8IDO1TDO2LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 US disclosed
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 US disclosed
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279219-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 TLR8 2353/4885IDO1 3159/4885TDO2 3934/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 TLR8 2353/4885IDO1 3159/4885TDO2 3934/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 TLR8 2684/4885IDO1 3008/4885TDO2 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.